Back to search results

Sarcopenia MRI Evaluation (SUSIE) in Heart Failure Patients

This study, called SUSIE, is looking at new ways to detect sarcopenia (a condition involving loss of muscle mass and strength) in people with heart failure. Researchers are using special MRI techniques, called MR Fingerprinting and P-MRS (Phosphorus-31 MR Spectroscopy), to get a clearer picture of muscle health. They want to see if these MRI methods can better identify sarcopenia in heart failure patients, compared to current methods. You might be able to join if you are at least 40 years old and have stable chronic heart failure with reduced pumping ability of your heart, or if you are a healthy volunteer without heart failure or sarcopenia. The study aims to gather results over 3 years.

Study design
This is an observational study involving up to 70 participants, including heart failure patients and healthy volunteers.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The anticipated results will be measured at 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04869813

Sarcopenia Magnetic Resonance Imaging Evaluation (SUSIE)

Enrolling by Invitation
Not specifiedAges 40+Observational
The Cleveland Clinic
~70 participants
Updated 2026-06-25 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Anticipated Results
Measured over 3 years

Conditions

Sarcopenia

Explore related trials

Heart FailureSarcopenia

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • W. H. Wilson Tang, MD · PRINCIPAL_INVESTIGATOR · The Cleveland Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Heart failure patients
Age ≥40 yrs
Stable chronic heart failure
Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less
Healthy Volunteers
Age ≥40 yrs
No diagnosed heart failure or sarcopenia

Exclusion

Heart failure patients
Healthy volunteers (controls)
Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease
Contraindications to MRI Contraindications to MRI
Heart pacemaker/defibrillator
Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires
Cochlear implant or other ear implants
Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)
Programmable shunt
Aneurysm clips and coils
Stents
Filters (for example, blood clot filters)
Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)

What this trial measures

  • Anticipated Results3 years

    This proposal is expected to produce information as to the change in T1, T2, muscle area, fat fraction, and PCr recovery rate values for heart failure patients with sarcopenia as compared to non-sarcopenic volunteers. Future work will expand upon this study to evaluate to progression of sarcopenia, and evaluate the prognostic value of imaging biomarkers (T1, T2, muscle area, fat fraction, PCr recovery) in predicting heart failure and sarcopenic related outcomes.